Press/Media
- 675 - 700 out of 2,094 results
Search results
-
-
What Is Benzene? A Break Down of the Chemical That Caused a Dry Shampoo Recall
22/11/22
3 items of Media coverage
Press/Media
-
Mesoblast (MSB: 99.50c) - PRE-MARKET CONFIRMATORY BULLISH SIGNAL FROM ITS ADR MARKET Wednesday November 23, 2022 08:11 AEDT
22/11/22
1 item of Media coverage
Press/Media
-
Mount Sinai Researchers to Study Racial Segregation and Patient Impact
Carol Horowitz, Nina Bickell & Lynne Richardson
21/11/22
1 item of Media coverage
Press/Media
-
-
Weekly: Mesoblast (MSB: 93.0c) increases 1.6% on low volume; +1.5c [1.6%]
21/11/22
1 item of Media coverage
Press/Media
-
Mesoblast (MSB: 91.50c) - PRE-MARKET CONFIRMATORY BULLISH SIGNAL FROM ITS ADR MARKET Monday November 14, 2022 08:11 AEDT
11/11/22 → 17/11/22
2 items of Media coverage
Press/Media
-
Mesoblast (MSB: 93.0c) - PRE-MARKET CONFIRMATORY BEARISH SIGNAL FROM ITS ADR MARKET Friday November 18, 2022 08:11 AEDT
17/11/22
1 item of Media coverage
Press/Media
-
Mount Sinai Researchers Building Database To Understand Racial Segregation And Its Impact On Patient Outcomes
Carol Horowitz, Nina Bickell & Lynne Richardson
16/11/22
1 item of Media coverage
Press/Media
-
-
New Biology Study Findings Have Been Reported from Icahn School of Medicine at Mount Sinai [A Proliferative To Invasive Switch Is Mediated By Srgap1 Downregulation Through the Activation of Tgf-(32 Signaling]
Angelo Gaitas, Umut Özbek & Jose Javier Bravo-Cordero
15/11/22
1 item of Media coverage
Press/Media
-
-
Mount Sinai Researchers Building Database to Understand Racial Segregation and Its Impact on Patient Outcomes
Carol Horowitz, Nina Bickell & Lynne Richardson
14/11/22
3 items of Media coverage
Press/Media
-
Mount Sinai Researchers Building Database to Understand Racial Segregation and Its Impact on Patient Outcomes
Carol Horowitz, Nina Bickell & Lynne Richardson
14/11/22
1 item of Media coverage
Press/Media
-
Can We Predict How Well Someone Will Respond to a Vaccine?
14/11/22
1 item of Media coverage
Press/Media
-
City life science rental activity more than tripled in Q3, report finds
14/11/22
1 item of Media coverage
Press/Media
-
Weekly: Mesoblast (MSB: 91.50c) in bottom 7% performers of All Ordinaries Index in past week; -3.5c [3.7%]
14/11/22
1 item of Media coverage
Press/Media
-
Bivalirudin safer and more effective than heparin for treating MI patients undergoing PCI: Lancet
13/11/22
1 item of Media coverage
Press/Media
-
Mesoblast (MSB: 89.50c) - PRE-MARKET CONFIRMATORY BEARISH SIGNAL FROM ITS ADR MARKET Friday November 11, 2022 08:11 AEDT
10/11/22
1 item of Media coverage
Press/Media
-
Mesoblast (MSB: 89.50c) weakens below moving average price, hits 36-day low
10/11/22
1 item of Media coverage
Press/Media
-
MIRIAM VIAZMENSKI Yale professor leads data-driven effort to understand why vaccine efficacy varies from person to person
10/11/22
2 items of Media coverage
Press/Media